Sign in
WithdrawnPhase 2

Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

Key facts

Who runs it
Rivus Pharmaceuticals, Inc.
Where
Orlando, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
17 Nov 2023
Ended
Mar 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • HU6
Record updated
9 January 2024
Why it stopped
The protocol was redirected by the FDA to another division and will be resubmitted at a future date.

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Able to understand the procedures and requirements of the study and provide written informed consent and authorization for protected health information disclosure
  • Willing and able to comply with the requirements of the study protocol
  • Male or female 18 to 70 years of age, inclusive, at time of informed consent
  • Body mass index (BMI) >28.0 kg/m2 and able to fit into the MRI machine
  • Subject has T2D meeting all of the following criteria:

Who cannot take part

  • Subject-reported history of weight gain or loss >5% in 3 months prior to screening
  • Body weight >450 pounds
  • The subject participates in programmed exercise >3 hours per week

Where in United States

  • AdventHealth Translational Research InstituteOrlando, United States

About the trial

What the trial wants to find out

This is a randomized, double-blind, placebo-controlled parallel group study of HU6 and placebo in subjects who are overweight or obese with T2D.

Read full original descriptionShow less

The study will be conducted in 4 stages.

The 2 groups in the trial

  • Active Treatment HU6Treatment being tested

    Subjects who are randomized to active study drug will receive 450mg of HU6 for 14 day and then 600mg of HU6 for 168 days. N = 24

    Treatment: HU6

  • PlaceboPlacebo, for comparison

    Placebo Comparator is non-active study drug. N = 24

    Treatment: HU6

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A 6-Month, Randomized, Double-Blind, Placebo-controlled, Phase 2a Study of the Effects of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
Record updated
9 January 2024